How much funding has KSQ Therapeutics raised?

KSQ Therapeutics has raised $156.0M in total funding, most recently a Series C round.

Who are KSQ Therapeutics's investors?

KSQ Therapeutics's investors include Baillie Gifford, Cowen Healthcare Investments, Invus, Lilly Asia Ventures, Flagship Pioneering, Polaris Partners.

When was KSQ Therapeutics founded?

KSQ Therapeutics was founded in 2015.

Where is KSQ Therapeutics headquartered?

KSQ Therapeutics is headquartered in Lexington, Massachusetts, United States.

What industry is KSQ Therapeutics in?

KSQ Therapeutics operates in Biotech, Healthcare.

How many employees does KSQ Therapeutics have?

KSQ Therapeutics has 51-200 employees.

KSQ Therapeutics

The ambition to cure

Lexington, United States · Founded 2015 · $156.0M raised

Biotech

Healthcare

Headquarters: Lexington, Massachusetts
Employees: 51–200
Founded: 2015
Business Model: B2B

Website: ksqtx.com
Total Funding: $156.0M
Last Round: $80.0M Series CSep 2018
Rounds: 2

About

KSQ Therapeutics is a clinical-stage biotechnology company headquartered in Lexington, Massachusetts. Founded in 2015 and backed by Flagship Pioneering, KSQ has industrialized genome-wide CRISPR/Cas9 functional genomic screens (CRISPRomics platform) across cancer models and immune cell types to identify high-confidence therapeutic targets. The company's lead programs are eTIL (engineered Tumor-Infiltrating Lymphocyte) therapies, which knock out SOCS1 and Regnase-1 targets to dramatically boost T cell tumor-killing activity. KSQ has strategic partnerships with Takeda, Ono, and Roche for immuno-oncology programs, and has raised over $156M in funding. The company is advancing multiple eTIL candidates including KSQ-001EX and KSQ-004EX.

Summary

KSQ Therapeutics is a Biotech company based in Lexington, United States, founded in 2015. It has raised $156.0M in total across 2 rounds, most recently a $80.0M Series C round in Sep 2018. Investors include Baillie Gifford, Cowen Healthcare Investments and Invus.

LinkedIn X (Twitter)